Your browser doesn't support javascript.
Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses.
Negru, Paul Andrei; Miculas, Denisa Claudia; Behl, Tapan; Bungau, Alexa Florina; Marin, Ruxandra-Cristina; Bungau, Simona Gabriela.
  • Negru PA; Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.
  • Miculas DC; Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania. Electronic address: miculas.denisaclaudia@gmail.com.
  • Behl T; Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.
  • Bungau AF; Medicine Programm of Study, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
  • Marin RC; Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.
  • Bungau SG; Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania. Electronic address: sbungau@uoradea.ro.
Biomed Pharmacother ; 153: 113432, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1936095
ABSTRACT
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is considered the etiological agent of the disease that caused the COVID-19 pandemic, and for which there is currently no effective treatment. This pandemic has shown that the rapid identification of therapeutic compounds is critical (when a new virus with high transmissibility occurs) to prevent or reduce as much as possible the loss of human lives. To meet the urgent need for drugs, many strategies were applied for the discovery, respectively the identification of potential therapies / drugs for SARS-CoV-2. Molecular docking and virtual screening are two of the in silico tools/techniques that provided the identification of few SARS-CoV-2 inhibitors, removing ineffective or less effective drugs and thus preventing the loss of resources such as time and additional costs. The main target of this review is to provide a comprehensive overview of how in-silico tools have been used in the crisis management of anti-SARS-CoV-2 drugs, especially in virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses; also, completions were added to the way in which these methods came to meet the requirements of biomedical research in the field. Moreover, the importance and impact of the topic approached for researchers was highlighted by conducting an extensive bibliometric analysis.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Etiology study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2022 Document Type: Article Affiliation country: J.biopha.2022.113432

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Etiology study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2022 Document Type: Article Affiliation country: J.biopha.2022.113432